LN-229: Subcutaneous glioblastoma cancer tumor model



Subcutaneous mouse tumor models

Subcutaneously implanted tumor cells represent a convenient means to test novel potential anticancer drugs *in vivo*. A large variety of human and murine cell lines derived from both, solid tumors or leukemias, covering a wide range of tumor geno- and phenotypes, have been adapted to grow in a murine host, and thus allow testing of a compound in the appropriate tumor model.

LN-229 cells (CPQ-247)

Human LN-229 cells were isolated from a 60 years old female patient with a frontal parieto-occipital cortex glioblastoma. As routine quality controls, the cells are regularly checked for Mycoplasma contamination and authenticity (via STR DNA Typing).

Tumor growth in vivo

LN-229 cells harvested from tissue culture flasks are implanted subcutaneously into the left flank of mice. Resulting tumors are monitored by calipering twice weekly.

Animal weights are measured three times weekly.

Animal behaviour is monitored daily.

All mice are maintained in separated isolated housing at constant temperature and humidity.

Accessory services: tumor wet weight and volume measurement at necropsy, blood sampling, flow cytometry, paraffin embedding of tumor tissue, histological & pathological analysis, cytokine determination, provision of tumor tissue for target validation.




Figure 1: Tumor growth of LN-229 cells in a subcutaneous xenograft in vivo model. Tumor volume, mean values +/- SEM

Study example

If you are interested in receiving information on potential positive controls please reach out to our Business Development team at requests@reactionbiology.com.